Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 7,325,356 | $267,888,269 | -14% | 3.09% |
| 2. | 2,244,400 | $82,077,708 | +52% | 0.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.07 | 3,315 | $49,957.05 | 17,287,081 | 2025-09-18 | Filing | |
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.57 | 900 | $32,913.00 | 14,954 | 2026-10-01 | Filing | |
| $36.08 | 16,850 | $607,948.00 | 15,854 | 2026-10-01 | Filing | |
| $36.62 | 200,000 | $7,324,000.00 | 1,599,154 | 2026-09-30 | Filing | |
| $40.38 | 600 | $24,228.00 | 9,900 | 2026-09-15 | Filing | |
| $39.65 | 4,338 | $172,001.70 | 10,500 | 2026-09-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 37,872 | $1,384,995 | 0.84% | |
| 2. | 18,332 | $670,401 | 0.04% | |
| 3. | 17,791 | $650,617 | 0.02% | |
| 4. | 10,707 | $391,555 | 0% | |
| 5. | 4,113 | $150,412 | 0.01% |
News See All
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization.
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension.
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%
Roivant Sciences Ltd.
What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) and Priovant Therapeutics have moved quickly to commercialize Lisraya following its FDA approval for dermatomyositis.
12 Best Growth Stocks Trading in Oversold Territory
In this article, we will discuss the 12 Best Growth Stocks Trading in Oversold Territory.
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks to buy with highest upside potential. Guggenheim lifted the price target on Roivant Sciences Ltd.
10 Best Healthcare Stocks to Buy with Highest Upside Potential
In this article, we will look at the 10 Best Healthcare Stocks to Buy with the Highest Upside Potential.
15 High Growth Stocks to Buy and Hold for the Next Decade
In this article, we will look at the 15 High Growth Stocks to Buy and Hold for the Next Decade.
Hedge Fund Resource Center